What is Gemelli Biotech?
Gemelli Biotech is dedicated to fostering a global family of healthy individuals by harnessing the power of the microbiome. The company's core mission involves supporting the discovery of innovative diagnostics and therapeutics for the human microbiome, bringing biotechnology advancements to market through a fiscally responsible and socially conscious approach. Their work is centered on leveraging biotechnology innovations to address unmet needs in health and wellness.
How much funding has Gemelli Biotech raised?
Gemelli Biotech has raised a total of $19M across 1 funding round:
Series A
$19M
Series A (2022): $19M with participation from Carolina Angel Network, CerraCap Ventures, Cedars-Sinai, and Blue Ox Healthcare Partners
Key Investors in Gemelli Biotech
Carolina Angel Network
Carolina Angel Network connects UNC alumni and friends to early-stage startups affiliated with the university, facilitating high-growth investment opportunities. The organization curates 4-6 investment opportunities annually for accredited investors, leveraging a strong network and professional backgrounds for due diligence.
CerraCap Ventures
Cerracap Ventures is a venture capital firm that focuses on industrializing innovation by investing in early-stage companies across various sectors. They aim to support founders and technologists by providing strategic guidance, customer connections, and resources to scale their businesses.
Cedars-Sinai
Cedars-Sinai Medical Center is a non-profit academic medical center in the U.S., with clinical programs ranging from primary care to specialized treatments for rare, complex and advanced illnesses. They serve the community through its Medical Network and through wide-ranging programs that improve the health of the most vulnerable residents of Los Angeles.
What's next for Gemelli Biotech?
With the recent major strategic investment, Gemelli Biotech is poised for significant expansion and further development of its pipeline. The enterprise-level funding suggests a focus on scaling operations, advancing clinical trials, and potentially broadening its market reach. This capital infusion will likely accelerate the company's efforts to translate its microbiome research into tangible health solutions, positioning Gemelli Biotech as a key player in the evolving biotechnology landscape.
See full Gemelli Biotech company page
